BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 24917231)

  • 1. Determination of clozapine in serum of patients with schizophrenia as a measurement of medication compliance.
    Mennickent S; Sobarzo A; Vega M; de Diego M; Godoy G; Rioseco P; Saavedra L
    Int J Psychiatry Clin Pract; 2010 Mar; 14(1):41-6. PubMed ID: 24917231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic alliance, a stake in schizophrenia].
    Charpentier A; Goudemand M; Thomas P
    Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series.
    Se Hyun Kim ; Dong Chung Jung ; Yong Min Ahn ; Yong Sik Kim
    J Psychopharmacol; 2010 Jul; 24(7):981-6. PubMed ID: 19942641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clozapine maintenance therapy in schizophrenia.
    Gaszner P; Makkos Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):465-9. PubMed ID: 15093952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy.
    Patel NC; Crismon ML; Miller AL; Johnsrud MT
    Pharmacotherapy; 2005 Sep; 25(9):1242-7. PubMed ID: 16164397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
    Misdrahi D; Llorca PM; Lançon C; Bayle FJ
    Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.
    Holzinger A; Loffler W; Muller P; Priebe S; Angermeyer MC
    J Nerv Ment Dis; 2002 Sep; 190(9):597-603. PubMed ID: 12357093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
    Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
    Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world.
    Mortimer AM; Singh P; Shepherd CJ; Puthiryackal J
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):49-55. PubMed ID: 20643629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Facilitating compliance with antipsychotic medication.
    Marder SR
    J Clin Psychiatry; 1998; 59 Suppl 3():21-5. PubMed ID: 9541334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on clozapine treatment at the Charles Perrens Hospital in Bordeaux, 15 years after its marketing].
    Mercier C; Bret P; Bret MC; Queuille E
    Encephale; 2009 Sep; 35(4):321-9. PubMed ID: 19748368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with antipsychotic medication adherence in community-based patients with schizophrenia in Hong Kong: a cross sectional study.
    Bressington D; Mui J; Gray R
    Int J Ment Health Nurs; 2013 Feb; 22(1):35-46. PubMed ID: 22738372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
    Rosenheck R; Cramer J; Xu W; Thomas J; Henderson W; Frisman L; Fye C; Charney D
    N Engl J Med; 1997 Sep; 337(12):809-15. PubMed ID: 9295240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing and monitoring clozapine in Christchurch.
    McKean A; Vella-Brincat J; Begg E
    Australas Psychiatry; 2008 Aug; 16(4):263-7. PubMed ID: 18668375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reason for clozapine cessation.
    Pai NB; Vella SC
    Acta Psychiatr Scand; 2012 Jan; 125(1):39-44. PubMed ID: 22017729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
    Rajkumar AP; Poonkuzhali B; Kuruvilla A; Jacob M; Jacob KS
    Int Clin Psychopharmacol; 2013 Jan; 28(1):50-6. PubMed ID: 23104241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia.
    Lewis SW; Barnes TR; Davies L; Murray RM; Dunn G; Hayhurst KP; Markwick A; Lloyd H; Jones PB
    Schizophr Bull; 2006 Oct; 32(4):715-23. PubMed ID: 16540702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations.
    Paz E; Bouzas L; Hermida J; Brenlla J; Tutor JC
    Clin Biochem; 2008 May; 41(7-8):603-6. PubMed ID: 18280253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia.
    Kim JH; Kim SY; Ahn YM; Kim YS
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):301-5. PubMed ID: 16309807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.